Key result
Monitoring unfractionated heparin with the antifactor Xa assay may require fewer dose adjustments and reach therapeutic ranges faster than aPTT, though clinical outcome data remain limited.
Why the study?
Drawbacks of aPTT monitoring for UFH, such as interpatient variability and reagent specificity, prompted the use of alternative assays like the antifactor Xa assay.
Antifactor Xa monitoring for unfractionated heparin may overcome the limitations of aPTT by providing a more direct and reliable measure of heparin activity.
No takes yet. Share an insight, caveat, or question.
UFH advantages support its ICU use despite renal variability; leaves open optimal monitoring strategies in critically ill patients.
Parker et al. (2019) conducted a review in Thromboembolic disorders requiring unfractionated heparin. Antifactor Xa monitoring vs. Activated partial thromboplastin time (aPTT) monitoring was evaluated. Monitoring unfractionated heparin with the antifactor Xa assay may require fewer dose adjustments and reach therapeutic ranges faster than aPTT, though clinical outcome data remain limited.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: